In agreement, src inhibition was shown to reduce Tks5 levels and podosome numbers, to decrease aECM invasion and to reverse fibrosis in PCLS (Fig. 7) and to attenuate BLM-induced pulmonary fibrosis in vivo when administered by inhalation (Fig. 8). This evidence concerns the gene SH3PXD2A and pulmonary fibrosis.